Clinical trial Recruiting at 1 site Interventional Ages 8 to 16

Social cognition testing for 8–16-year-olds with autism, ADHD, or atypical development

Official title: Characterization of Social Cognition Profiles in Children and Adolescents With Neurodevelopmental Disorders: a Clinical Study Using a Multidimensional Battery

Run by Assistance Publique - Hôpitaux de Paris · NCT07439276 · Data updated 2026-11-12

This project will test a multidimensional social-cognition battery in French-speaking 8–16-year-olds with autism, ADHD, or atypical neurodevelopment to see if it better identifies social processing differences.

Quick facts

Study typeInterventional
Ages8 Years to 16 Years
SexAll
Enrollment100 (estimated)
SponsorAssistance Publique - Hôpitaux de Paris
Academic / other
Locations1 site (Paris)
StatusRecruiting
StartedApril 8, 2026
Main results expectedApril 2029
Study endsApril 2029
Registry record updatedApril 16, 2026
Trial IDNCT07439276 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Eligible patients are French-speaking children and adolescents aged 8–16 with a diagnosis of autism spectrum disorder, ADHD, or multiple complex/atypical neurodevelopmental presentations, who have an IQ above 70 and stable psychotropic medication for at least six weeks.

Probably not a fit

Children younger than 8 or older than 16, non–French speakers, those with IQ ≤ 70, active neurological disorders (e.g., active epilepsy), or recent changes in psychotropic medication are unlikely to be eligible or to benefit from these specific assessment procedures.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical project uses a multidimensional battery to measure four core domains of social cognition—emotion processing, social perception, theory of mind, and attributional style—in children and adolescents aged 8 to 16. Participants diagnosed with autism spectrum disorder, attention-deficit/hyperactivity disorder, or atypical neurodevelopment will complete standardized tests and questionnaires administered in French, with cognitive functioning confirmed by an IQ > 70. The protocol excludes children with active neurological disorders or recent medication changes and collects detailed profiles to map patterns of socio-cognitive strengths and deficits across diagnostic groups. Investigators aim to use these profiles to refine clinical characterization and identify disorder-specific therapeutic targets and assessment gaps.

Why it matters

Potential benefit: If successful, the battery could help clinicians detect specific social-cognitive difficulties earlier and guide more tailored interventions for children with neurodevelopmental disorders.

How similar studies have gone: Components of this approach (e.g., theory of mind or emotion-processing tests) have shown utility in prior pediatric research, but a single validated multidimensional battery for broad clinical use in 8–16-year-olds remains relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Children and adolescents aged 8 to 16 years
* Proficiency in French (native language)
* Information and consent obtained from those holding parental authority, and agreement from the child or adolescent
* No recently modified (\<6 weeks) psychotropic medication from the following categories: antidepressants, anxiolytics, antipsychotics, psychostimulants, mood stabilizers.
* IQ above 70 (WISC-V)
* Criteria for Neurodevelopmental Disorders: Diagnosis of Autism Spectrum Disorder or Attention Deficit Hyperactivity Disorder (according to DSM-5)
* Multiple complex developmental disorder : Symptoms characteristic of a neurodevelopmental disorder without meeting all the criteria for a specific disorder and presence of multiple complex developmental disorder criteria with at least 5 elements from the specified categories.

Exclusion Criteria:

\- Having an active neurological disorder (e.g., active epilepsy)

Where it's running

  • Hôpital Necker-Enfants Malades
    Paris, France
    Recruiting

Study contacts

  • Principal investigator: Dorothée Leunen — Assistance Publique - Hôpitaux de Paris
  • Study coordinator: Dorothée Leunen
  • Email: dorothee.leunen@aphp.fr
  • Phone: 0171196346

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.